Literature DB >> 3969322

Loss of intellectual function in children with phenylketonuria after relaxation of dietary phenylalanine restriction.

M R Seashore, E Friedman, R A Novelly, V Bapat.   

Abstract

Fourteen patients with classic phenylketonuria (PKU) were treated with a phenylalanine restricted diet from early infancy. All had satisfactory dietary control, with serum phenylalanine concentrations ranging between 2 to 5 mg/dL. Dietary restriction was discontinued in all these children between ages 5 and 6 years, and a free diet allowed. Developmental testing was performed using the Cattell Infant Intelligence Scales (1 to 2 years), Stanford-Binet Intelligence Scale (2 to 4 years), Wechsler Intelligence Scale for Children (WISC) and the revised version (WISC-R) (less than 5 years). Mean IQ for the group (Stanford-Binet and WISC) at termination of dietary therapy was 104 +/- 13. Four to 7 years after discontinuation of dietary therapy, mean IQ for the group was 90 +/- 13. The severity correlated, to some degree, with duration of unrestricted diet, but not with initial serum phenylalanine concentrations, age at initiation of therapy, or IQ at time diet was discontinued. Several children are experiencing difficulties, both attentional and academic, in school. Two children have had a change in the EEG from normal to abnormal. Neurologic testing performed after 4 to 7 years off diet demonstrated deficits in visual-motor integration or cognitive problem-solving in most children. The mean developmental age for the group for perceptual-motor integration was 1.2 years below the mean chronologic age of the group. This deterioration in intellectual function suggests that discontinuation of the phenylalanine-restricted diet is hazardous for some children with classic phenylketonuria.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3969322

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  18 in total

1.  Effect of genotype on changes in intelligence quotient after dietary relaxation in phenylketonuria and hyperphenylalaninaemia.

Authors:  L G Greeves; C C Patterson; D J Carson; R Thom; M C Wolfenden; J Zschocke; C A Graham; N C Nevin; E R Trimble
Journal:  Arch Dis Child       Date:  2000-03       Impact factor: 3.791

2.  Randomised controlled trial of tyrosine supplementation on neuropsychological performance in phenylketonuria.

Authors:  M L Smith; W B Hanley; J T Clarke; P Klim; W Schoonheyt; V Austin; D C Lehotay
Journal:  Arch Dis Child       Date:  1998-02       Impact factor: 3.791

3.  The effects of diet discontinuation in children with phenylketonuria.

Authors:  F M Slijper; J Huisman; M M Hendrikx; A F Kalverboer; L vd Schot
Journal:  Eur J Pediatr       Date:  1988-05       Impact factor: 3.183

4.  Large neutral amino acids in the treatment of phenylketonuria (PKU).

Authors:  R Matalon; K Michals-Matalon; G Bhatia; E Grechanina; P Novikov; J D McDonald; J Grady; S K Tyring; F Guttler
Journal:  J Inherit Metab Dis       Date:  2006-09-21       Impact factor: 4.982

5.  Phenylketonuric patients decades after diet.

Authors:  R O Fisch; P N Chang; S Weisberg; P Guldberg; F Güttler; M Y Tsai
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

6.  Neurological deterioration in adult phenylketonuria.

Authors:  D Villasana; I J Butler; J C Williams; S M Roongta
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

7.  Long-term follow up of patients with classical phenylketonuria after diet relaxation at 5 years of age. The Paris Study.

Authors:  F Rey; V Abadie; F Plainguet; J Rey
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

8.  Intelligence and professional career in young adults treated early for phenylketonuria.

Authors:  H Schmidt; P Burgard; J Pietz; A Rupp
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

9.  Information processing in patients with early and continuously-treated phenylketonuria.

Authors:  B A Stemerdink; J J van der Meere; M W van der Molen; A F Kalverboer; M M Hendrikx; J Huisman; L W van der Schot; F M Slijper; F J van Spronsen; P H Verkerk
Journal:  Eur J Pediatr       Date:  1995-09       Impact factor: 3.183

10.  Agoraphobia in phenylketonuria.

Authors:  S E Waisbren; H L Levy
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.